If you are wondering whether GSK is still attractively priced after its recent run, you are not alone and this article is for you. The share price closed at £20.38, with returns of a 7.4% decline over ...

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

"After you take some well-deserved time off … let's do it again!" the chair of RAPT Therapeutics' board tells co-founder-CEO ...

FDA Commissioner Marty Makary highlighted rapid approvals of the lung cancer drug Zongertinib and the multiple myeloma ...

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise ...

Drugmaker GSK PLC won’t have to answer a securities fraud class action stemming from its concealment of a link between Zantac and a cancer-causing substance because it was filed too late.

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

It posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales ...

In a scathing rebuke (PDF) to AstraZeneca, the FDA cited “critical data quality issues that affect key analyses, including the primary endpoint” within a dataset for Saphnelo (anifrolumab) for the ...

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...

GSK struck a deal to buy Canada’s 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.